Resveratrol (3,4',5-trans-trihydroxystilbene), a phytoalexin present in grapes and red wine, is emerging as a natural compound with potential anticancer properties. Here we show that resveratrol can induce growth inhibition and apoptosis in MDA-MB-231, a highly invasive and metastatic breast cancer cell line, in concomitance with a dramatic endogenous increase of growth inhibitory/proapoptotic ceramide. We found that accumulation of ceramide derives from both de novo ceramide synthesis and sphingomyelin hydrolysis. More specifically we demonstrated that ceramide accumulation induced by resveratrol can be traced to the activation of serine palmitoyltransferase (SPT), the key enzyme of de novo ceramide biosynthetic pathway, and neutral sphingomyelinase (nSMase), a main enzyme involved in the sphingomyelin/ceramide pathway. However, by using specific inhibitors of SPT, myriocin and Lcycloserine, and nSMase, gluthatione and manumycin, we found that only the SPT inhibitors could counteract the biological effects induced by resveratrol. Thus, resveratrol seems to exert its growth inhibitory/apoptotic effect on the metastatic breast cancer cell line MDA-MB-231 by activating the de novo ceramide synthesis pathway.
, colon (16) , and breast (11, 17) cancer. A few studies have focused on the possible molecular targets, which could explain the antiproliferative/apoptotic effects of resveratrol. The induction of cell cycle arrest by resveratrol has been associated to a decreased level of cyclin D1 (18) and upregulation of both the oncosuppressor p53 and the cyclin kinase inhibitor p21/Waf1/CIP1 (19) . Resveratrol was shown to inhibit other known key regulators of cell proliferation such as PKC (20) . Cell death induction was shown to be associated to BCL2 phosphorylation (21) , BAX mitochondrial translocation (22) , and inhibition of AKT and FAK activity (23) . Resveratrol was reported to inhibit ribonucleotide reductase (24) , therefore interfering with DNA synthesis. Moreover resveratrol was seen to inhibit both the activity and transcription of COX1 and COX2 (15, 25) .
We set out to study the mechanism of action of resveratrol in breast cancer cells. We know that resveratrol structure resembles the structure of synthetic estrogen diethylstilbestrol. However, resveratrol fails to mimic estrogen activity in Wistar rats (26) and the antiproliferative effect of resveratrol in breast cancer cells is apparently unrelated to the cell hormone-receptor status (11, 17) . Interestingly, resveratrol contains a phenol group like some chemopreventive and chemotherapeutic agents, including fenretinide (27, 28) , etoposide (29) , and ∆9-tetrahydrocannabinol (30) , which are known to exert their antiproliferative activity by increasing the level of endogenous ceramide. Ceramide is the key component of complex sphingolipids and the mediator of many intracellular events such as proliferation, differentiation, senescence, and cell death (31) . For this reason, we hypothesized that the antiproliferative/apoptotic effect of resveratrol in breast cancer cells might involve the induction of endogenous ceramide.
Indeed, we found that resveratrol induces growth inhibition/apoptosis in MDA-MB-231, a highly metastatic ER-negative breast cancer cell line, in concomitance with a consistent accumulation of endogenous ceramide in a dose-and time-dependent fashion.
We also found that the accumulation of ceramide induced by resveratrol is due to the combined activation of both the de novo ceramide synthesis pathway and the sphingomyelin/ceramide cycle. However, only inhibitors of serine palmitoyltransferase (SPT), the key enzyme of de novo ceramide synthesis, were seen to rescue resveratrol-treated cells from apoptosis. Our overall data indicate that ceramide from de novo synthesis is the likely mediator of the growth inhibitory/apoptotic effects induced by resveratrol in the MDA-MB-231 cell line.
MATERIALS AND METHODS

Reagents
Resveratrol was from Cayman Chemical Company (Ann Arbor, MI) and was dissolved in ethanol before use. L-cycloserine, myriocin, glutathione, manumycin, desipramine, SRB, trypan blue, and propidium iodide (PI) were from Sigma-Aldrich (St. Louis, MO). L-cycloserine and desipramine were dissolved in sterile water, myriocin in methanol, manumycin in DMSO, and glutathione in culture medium, before use. Ceramide from porcine brain, used for internal standard, was from Avanti Polar Lipids Inc., (Alabaster, AL). [γ 32 -P]ATP (3 Ci/µmol) and L-[ 3 H]serine (23 Ci/mol) were from Perkin Elmer Life Sciences Inc., (Boston, MA). [4, H]dihydrosphingosine (60 Ci/mmol) was from Bio Trend (Koln, Germany). [9,10- 
PARP cleavage assay
Cytosolic proteins were obtained by centrifugation at 15,000 g for 10 min of extracts of cells treated for 48 h with vehicle (control) or with 32 µM resveratrol, lysed for 15 min on ice in lysis buffer (50mM Tris-HCl, pH 7.5; 150 mM NaCl; 10% glycerol; 1% Triton X-100; 100 mM NaF; 10 mM sodium-pyrophosphate; 5 µg/ml aprotinin; 5 µg/ml leupeptin; 1 mM phenylmethanesulfonylfluoride). Proteins (10 µg) were separated on 8% SDS-polyacrylamide minigel and transferred to nitrocellulose membranes. Membranes were incubated in blocking solution (5% nonfat dry milk in 0.05% Tween 20 in 50 mM Tris, 150 mM NaCl) and anti-PARP antibody (1:500 dilution in blocking solution). PARP, intact protein, and cleaved fragment were visualized by ECL.
Analysis of cell cycle profile
Cell cycle profile was analyzed by flow cytometric analysis by DNA staining with PI. Cells were treated for 48 h with vehicle (control) or with 16 µM resveratrol, washed with phosphate buffered saline, and stained at 4°C overnight with PI (50 µg/ml in 0.1% sodium citrate and 0.1% Triton X-100). Stained cells were analyzed by flow cytometry (Beckton-Dickinson, Mountain View, CA). Apoptotic cells were determined by their hypochromic staining profile (sub-G 0 /G 1 DNA content).
Quantification of endogenous ceramide
Total endogenous ceramide level was measured using the diacylglycerol kinase assay (DGK) as described previously (32, 33) . For dose-response experiment, cells were treated for 48 h with vehicle or with resveratrol from 1 to 64 µM. For time-course experiments, cells were treated with vehicle or with 32 µM resveratrol for up to 48 h. Then, cells were collected and lipids were extracted according to Bligh and Dyer (34) . The organic phase was divided in 1/2 and 1/6 aliquots, dried, and used for ceramide measurement and total phospholipid measurement (35), respectively. Briefly, 30 nmol of extracted lipids were incubated at room temperature for 45 min in the presence of β-octylglucoside/dioleoylphosphatidylglycerol micelles, 2 mM dithiothreitol, 5 µg of proteins of DGK containing membranes (kindly provided from Dr. Y.A. Hannun, Charleston, SC), and 1 mM ATP (mixed with [γ-P 32 ]ATP at a final radioactivity of 13 µCi/ml) in a final volume of 0.1 ml. At the end of reaction, lipids were extracted according to Bligh and Dyer.
[ 32 P]ceramide-1-phosphate was determined by TLC separation in chloroform/acetone/methanol/acetic acid/water (10/4/3/2/1, by volume) and visualization by autoradiography, followed by scraping the radioactive ceramide-1-phosphate spots and counting in a scintillator counter. Ceramide level referred to the level of total phospholipids.
SPT assay
SPT activity was measured according to a described method (36) on microsomal membranes obtained from 8 × 10 7 cells treated for 48 h with vehicle (basal activity) or with 32 µM resveratrol. Triplicate samples were used for each treatment.
Sphingomyelinase assay
The activity of both nSMase and aSMase was determined using radiolabeled substrate in a mixed micelle assay (37) on membranes from cell lysates (38) from 8 × 10
7 cells treated for 48 h with vehicle (basal activity) or with 32 µM resveratrol. Duplicate samples were used for each treatment.
Radiolabeling of de novo ceramide pathway
Cells were seeded in 6-wells plates at 4 × 10 5 cells/well, allowed to adhere 24 h, and labeled with 0.75 µCi/ml of [ 3 H]palmitate (specific radioactivity, 43 Ci/mmol) in the presence of 32 µM resveratrol for 48 h at 37°C (29) . Cells were then washed, scraped, and harvested by centrifugation. Lipids were extracted according to Bligh and Dyer (34) and, after mild alkaline hydrolysis, were separated by TLC, using chloroform/methanol/NH 4 OH 2 N, 40/7.5/1, by volume. Ceramide spots were visualized by fluorography, scraped, and counted in a scintillation counter. Values referred to total phospholipids.
Radiolabeling of cellular sphingomyelin and ceramide mass
Cells were seeded in 6-wells plates at 4 × 10 5 cells/well, allowed to adhere 24 h, and labeled by adding 0.2 µCi/well of [ 3 H]dihydrosphingosine (specific activity, 60 Ci/mmol) for 48 h at 37°C and further incubated in cold medium containing 32 µM resveratrol for 48 h. Cells were collected by scraping and used for lipid extraction according to Bligh and Dyer. Lipids were separated by TLC using chloroform/methanol/NH 4 OH 2 N, 40/7.5/1, by volume for ceramide analysis or chloroform/methanol/formic acid/water, 65/25/8.9/1.1, by volume for sphingomyelin analysis. Ceramide and sphingomyelin spots were visualized by fluorography, scraped, and counted. Values referred to total phopholipids.
RT-PCR of human SPT
Total cellular RNA was isolated from 0.4 × 10 5 human MDA-MB-231 cells treated with or without 32 µM resveratrol for 48 h. RNA was subjected to RT-PCR on a GeneAmp PCR System 2770 (AB Applied Biosystems) as follows: a 25 µl reaction containing 200 ng of RNA, 0.4 µM each primer, 1X Reaction Mix (Invitrogen), and 0.5 µl Superscript/Taq Polymerase enzyme (Invitrogen) was amplified in a GeneAmp PCR System 2770. The sample was reverse transcribed at 50°C for 30 min and heated to 94°C for 2 min. The resulting cDNA was amplified for 45 cycles by denaturation at 95°C for 30 s, primer annealing at 55°C for 40 s, and elongation at 72°C for 50 s. The primers used were as follows: human housekeeping (HPRT), 5′-CGTGGGTCCTTTTCACCAGCAAG-3′ and 5′-AATTATGGACAGGACTGAACGTC-3′; human SPT subunit 1 (hLCB1), 5′-AGGAGTCACTGAACACTATG-3′ and 5′-AGCTCTCTCCAGTTCTTCCT-3′; and human SPT subunit 2 (hLCB2), 5′-GTGGATGTTATGATGGGAACG-3′ and 5′-CATACGTCGTCTCGTCAAAG-3′.
Statistical analysis
Results are means ± SD. Statistical analysis was performed using ANOVA, and P values of <0.05 were considered significant.
RESULTS
Resveratrol has antiproliferative and proapoptotic effects on MDA-MB-231 cells
To assess the biological effect of resveratrol on MDA-MB-231 cells, we analyzed 1) cell proliferation, 2) cell viability, 3) colony formation, and 4) apoptosis. The results are shown in Fig. 1 . Growth inhibition assessed by SRB assay was close to 50% when cells were grown for 4 days at 16 µM resveratrol and close to 100% when cells were grown in the presence of 64 µM resveratrol (Fig. 1A) . IC 50 was calculated to be 20 µM. Cell viability was measured by trypan blue exclusion after 2 days of treatment with increasing doses of resveratrol. Viable cells were 62% of control at 16 µM and dropped to 28% of control at 64 µM resveratrol (Fig. 1B) . Colony formation was also dramatically inhibited by resveratrol. After 2 days of treatment with either 32 or 64 µM, the number of colonies was 42 and 11% of control, respectively (Fig. 1C) . Apoptosis was evaluated by detection of caspase-induced cleavage of PARP and PI staining of DNA followed by FACS analysis (Fig. 1D) . Presence of resveratrol as low as 16 µM was able to induce PARP cleavage seen as the appearance of the 86 kDa band. Treatment with 16 µM resveratrol for 2 days resulted in 24% apoptotic cells with sub-G 0 /G 1 DNA content. The content of apoptotic cells in the control was very low (1.6%).
Altogether these experiments show that resveratrol is able to significantly block cell proliferation, cell viability, and colony formation and induce apoptosis in the breast cancer cell line MDA-MB-231 in a dose-dependent manner.
Resveratrol induces ceramide accumulation
We tested whether accumulation of endogenous ceramide, a known proapoptotic lipid, is correlated with the biological effects induced by resveratrol. To this end, we incubated MDA-MB-231 cells for 48 h in the presence of increasing resveratrol concentrations ranging from 1 to 64 µM and evaluated the generation of total endogenous ceramide by DGK assay (Fig. 2A) . We observed that in cells exposed to 32 and 64 µM resveratrol ceramide increased ~5 and 10-fold, respectively, in comparison with untreated cells. The kinetics of ceramide accumulation in cells treated with 32 µM resveratrol displayed a nonlinear trend, with a lower increase in the first 24 h (Fig. 2B) .
From these data, we conclude that the induction of endogenous ceramide by resveratrol mirrors the induction of biological effects.
Resveratrol induces both de novo synthesis of ceramide and sphingomyelin hydrolysis
Next, we set out to identify whether resveratrol-induced ceramide accumulation can be traced to either de novo ceramide synthesis or sphingomyelin hydrolysis, or both. To test for the activation of the de novo ceramide synthesis pathway, we metabolically labeled cells with [ 3 H]palmitate for 48 h in the presence of 32 µM resveratrol. Radioactive lipids were then extracted and separated by TLC (Fig. 3A, upper panel) . We found that, the incorporation of radioactivity into ceramide was threefold higher in treated vs. untreated cells (Fig. 3A, lower panel) . To test whether the ceramide increase was due to sphingomyelin hydrolysis, we grew cells in the presence with [ 3 H]dihydrosphingosine for 48 h to radiolabel the endogenous sphingolipids as described in Materials and Methods. Then, we removed the radioactive medium and added fresh, nonradioactive medium alone or with 32 µM resveratrol for an additional 48 h. After separation by TLC (Fig. 3B , upper left and right panels, respectively), we quantified both the radioactive sphingomyelin and ceramide spots (Fig. 3B, lower left and right panel, respectively) . Apparently, resveratrol induced a concurrent decrease of sphingomyelin and increase of ceramide, thus indicating a conversion of sphingomyelin into ceramide.
To unequivocally identify whether enzymes involved in the de novo synthesis and sphingomyelin hydrolysis were activated by resveratrol, we assayed the activity of SPT, the rate limiting enzyme of de novo ceramide synthesis, and the activities of both neutral and acid sphingomyelinases (nSMase and aSMase) responsible for the hydrolysis of sphingomyelin into ceramide and phosphocholine. The enzyme activities were evaluated on enriched fractions of microsomal membranes of cells treated for 48 h with 32 µM of resveratrol and assayed in vitro by adding the specific substrate as described in Materials and Methods. SPT activity increased 1.5-fold in resveratrol-treated vs. untreated cells (Fig. 3C, left) . aSMase activity was not affected by resveratrol treatment (Fig. 3C, middle) . In contrast, nSMase activity dramatically increased 4.2-fold in treated vs. untreated cells (Fig. 3C, right) .
To shed light on the regulation of SPT activity, we determined the mRNA levels of the SPT1 (regulatory) and SPT2 (catalytic) subunits by RT-PCR. No increases in the message levels of either subunit were observed (Fig. 3D ).
Altogether these results show that the increase of ceramide level in MDA-MB-231 cells in response to resveratrol is due both to the stimulation of de novo ceramide synthesis via SPT activation and to the hydrolysis of sphingomyelin via nSMase activation.
Inhibitors of de novo ceramide synthesis can counteract the biological effects of resveratrol
To understand the biological role of the two different pools of ceramide induced upon resveratrol treatment, we treated MDA-MB-231 cells with resveratrol alone or in combination with inhibitors of the key enzymes involved in de novo ceramide synthesis and sphingomyelin hydrolysis. We tested two SPT inhibitors, L-cycloserine (1 mM final concentration) and myriocin (5 µM final concentration), the nSMase inhibitors glutathione (15 mM final concentration) and manumycin (1 µM final concentration), and the aSMase inhibitor desipramine (5 µM final concentration) each alone or in combination with 32 µM resveratrol for 48 h. Viable cells were evaluated by trypan blue exclusion (Fig. 4A) . Of the inhibitors, only L-cycloserine and myriocin counteracted resveratrol-induced cell death (from 40% viability of resveratrol alone to 78 and 75% viability of resveratrol combined with L-cycloserine or myriocin, respectively). FACS analysis of apoptotic cells after treatment with resveratrol and the SPT inhibitor L-cycloserine showed that L-cycloserine significantly reduced the percentage of apoptotic cells from 24% (resveratrol alone, Fig. 1D , lower panel) to 9% (resveratrol plus L-cycloserine, Fig. 4B, upper  panel) . Apoptotic cells after L-cycloserine alone were 4% (Fig. 4B, upper panel ) and 1.6% in cells exposed to the vehicle (Fig. 1D, lower panel) . L-cycloserine was also able to abrogate caspase-activation induced by resveratrol as shown by PARP cleavage assay (Fig. 4B, lower  panel) .
From this set of experiments, we conclude that of the overall ceramide induced by resveratrol treatment only the fraction of ceramide from de novo synthesis is effective in inducing apoptosis.
DISCUSSION
In this study, we show that resveratrol has a potent antiproliferative and proapoptotic effect on MDA-MB-231, a highly invasive and metastatic cell line from human breast cancer, known to be resistant to several anticancer drugs (39) (40) (41) (42) . The resveratrol-induced biological effect is dose dependent and correlates with a dramatic increase of endogenous ceramide. We further show that resveratrol-induced ceramide accumulation is consequent to both activation of SPT, the key, rate-limiting enzyme of the de novo synthesis of sphingolipids, and nSMase, the main enzyme responsible for the sphingomyelin/ceramide cycle. However, we demonstrate that only the ceramide induced via the de novo synthesis pathway is implicated in the resveratrol-induced apoptosis.
First, we showed that the resveratrol-induced biological effects on growth and apoptosis are dose dependent (Fig. 1) . We also estimated that resveratrol has an IC 50 of 20 µM comparable to the IC 50 of some other chemopreventive and chemotherapeutic agents. The profound biological effects of resveratrol in MDA-MB-231, which is an ER-negative cell line, confirm that resveratrol cellular response is independent of the ER status as previously seen in other breast (7, 11, 12, 14, 17) and prostate (8) cell lines.
We found that the antiproliferative/proapoptotic effect of resveratrol is concomitant to a dramatic increase of endogenous ceramide, a master lipid mediator capable of regulating cellular targets involved in proliferation and apoptosis (43) . Indeed, up to a 10-fold ceramide increase has been observed in resveratrol-treated cells as determined by the DGK assay ( Fig. 2A) . Ceramide levels as well as the biological response are dose and time dependent. We also found that resveratrol induced 1) a 50% increase over the activity of SPT, the key enzyme of de novo ceramide synthesis; and 2) a 4.2-fold activation of nSMase (Fig. 3C) . The contribution of both SPT and nSMase pathways to the observed ceramide increase was demonstrated by metabolic labeling experiments. Cells labeled with [ 3 H]palmitate, a precursor to the SPT/ceramide synthase substrate palmitoylCoA, in the presence of resveratrol, led to an increase of labeled ceramide, thus implying the involvement of de novo ceramide synthesis (Fig. 3A) . In addition, prelabeling of cells with [ 3 H]dihydrosphingosine, followed by resveratrol treatment, led to a concurrent increase of labeled ceramide (up to 4-fold of its basal value) and a decrease of labeled sphingomyelin (Fig. 3B) . The sum of radiolabeled ceramide and sphingomyelin was the same in the samples from control and treated cells, making us conclude that the data reflect the conversion of sphingomyelin into ceramide.
We also demonstrated that some resveratrol-induced ceramide is indeed responsible for the resveratrol-induced biological effects by using ad hoc inhibitors of the enzymes involved in ceramide generation. Specifically, SPT inhibitors were able to counteract resveratrol-induced inhibition of cell proliferation. In contrast, nSMase inhibitors did not affect the resveratrolinduced biological response (Fig. 4A) .
Our data are interesting in light of a recent report on the effects of paclitaxel and etoposide on prostate cancer cells (44) , showing that sphingomyelin hydrolysis is an event secondary to the activation of de novo ceramide synthesis and that this loop is PKCδ controlled. Resveratrolinduced ceramide accumulation may also be due to this dual domino effect mediated by PKCδ. Despite that we do not have direct evidence of PKCδ involvement, our data provide indirect hints that this may be the case, including 1) evidence of nonlinear timing of ceramide formation, with an early latency and a late accumulation (Fig. 2B) ; 2) the activation of both de novo synthesis pathway and the hydrolysis of sphingomyelin (Fig. 3B); and 3 ) the reversion of growth arrest with SPT inhibitors but not with nSMase inhibitors (Fig. 4A) .
It may be noteworthy that resveratrol is capable of increasing the enzymatic activity of SPT like a few other agents presenting a phenol group in their molecule, such as fenretinide (27, 28) , etoposide (29) , and ∆9-tetrahydrocannabinol (30) . Whether, this structural feature is required to trigger SPT and consequently de novo ceramide accumulation remains to be demonstrated and may be of interest for designing and developing new anticancer agents. Interestingly, we found that stilbene, the nonphenolic structure core of resveratrol, is uneffective up to 64 µM to induce in growth inhibition of MDA-MB-231 cells (unpublished results). Although resveratrol concentrations required for the effects on cell death and ceramide generation are quite high and uncomparable with those obtained by common dietary intake, a systematic consume of food sources containing resveratrol may exert beneficial, (chemo)preventive effects on individuals with a high risk of breast cancer. Epidemiological studies in this direction are still lacking.
In conclusion, our study demonstrates that 1) resveratrol can induce apoptotic cell death of the drug-resistant, highly invasive and metastatic breast cancer cell line MDA-MB-231 and concurrent accumulation of ceramide via de novo synthesis and sphingomyelin hydrolysis and 2) the biologically effective ceramide is from de novo synthesis. Since the concentrations used in our study are similar to those obtained in vivo after oral administration of the drug and resulting in antitumoral activity (15, 45) , the current data warrant additional investigation of resveratrol as a potential (chemo)therapeutic agent for metastatic breast cancer. Finally, it will be interesting to further pursue the dissection of the common biochemical mechanism leading to ceramide accumulation by resveratrol and other SPT-activating drugs used in cancer treatment in light of rationally improving chemotherapy. 
